Abstract
BioFactorsVolume 46, Issue 3 ISSUE HIGHLIGHTSFree Access ISSUE HIGHLIGHTS First published: 12 June 2020 https://doi.org/10.1002/biof.1664AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat 306 COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin Theoharis C. Theoharides The recent corona virus [severe acute pulmonary syndrome (SARS-CoV-2)] infects cells, especially in the lungs, via its spike protein binding to a receptor on the surface called Angiotensin Converting Enzyme 2 (ACE2). Pulmonary mast cells express this receptor making them prime targets, following which they release a storm of pro-inflammatory cytokines that contribute to the pathogenesis of COVID-19, especially SARS. The natural flavonoid luteolin, as well as its structural analogues eriodictyol and quercetin (Green box and lines), can block SARS-CoV-2 binding and also inhibit mast cell release of cytokines. Combination of these natural molecules, preferably in olive pomace oil to increase oral bioavailability, could be useful prophylactically against COVID-19. Figure 1Open in figure viewerPowerPoint REFERENCE 1Theoharis C. Theoharides. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. BioFactors. 2020; 46: 306– 308. Volume46, Issue3May/June 2020 FiguresReferencesRelatedInformation
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call